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Small interfering RNAs (siRNAs) technology has emerged as a promising potential treatment for viral, genetic diseases and
cancers. Despite the powerful therapeutic potential of siRNA, there are challenges for developing efficient and specific delivery
systems for systemic administration. There are extracellular and intracellular barriers for nanoparticle-mediated delivery. First,
nanoparticles are rapidly cleared from the circulation by the reticuloendothelial system (RES). Second, following their cellular
uptake, nanoparticles are trapped in endosomes/lysosomes, where siRNA would be degraded by enzymes. In this review, we
describe strategies for grafting a polyethylene glycol (PEG) brush to the nanoparticles for evading RES, such that they may effect-
ively accumulate in the tumor by the enhanced permeability and retention (EPR) effect. PEG has to shed from the nanoparticles
to allow close interaction with the tumor cells. Current strategies for facilitating endosome escape, such as ion pair formation,
“proton sponge effect”, destabilizing endosome membrane, and hydrophobic modification of the vector, are discussed.
1. Introduction
RNA interference was firstly discovered by Fire et al. in 1998
[1], and this technology has emerged as a powerful tool for
analyzing gene function and inhibiting gene expression in
cell culture and in animal models. Small interfering RNA
(siRNA), resulting from the cleavage of longer double strand-
ed RNA precursors by endonuclease dicer, could enter the
RNA-induced silencing complex, where the complementary
mRNA is degraded and as a result the expression of the
corresponding protein is reduced [2, 3]. However, systemic
delivery of naked siRNA is limited by rapid blood clearance,
RNA degradation, and poor cellular penetration due to the
large molecular weight and negative charge of siRNA.
The success in the application of siRNA for cancer thera-
py is highly dependent on the development of vectors which
are nontoxic and can selectively and efficiently deliver siRNA
into the specific tissue in vivo [4, 5]. Gene therapy vectors
can be generally divided into two categories: viral vectors and
nonviral vectors. Viral vectors are highly efficient, but the
drawbacks of high cost, safety concerns and immunity signif-
icantly limit their application. To over the limitations of viral
vectors, nonviral vectors have been widely developed as alter-
natives. The majority of nonviral vectors are based on syn-
thetic polymers and lipids. To date, these synthetic vectors
are still relatively less efficient than viral vectors. It is a re-
sult of many barriers, extracellular as well as intracellular,
encountered between the site of administration and the
nucleus or cytoplasm of the target cells for DNA or siRNA
delivery [5–8]. Extracellular barriers include condensing
nucleic acid into stable complexes which would not be deas-
sembled in the solution and blood, maintaining stability
and circulation of nanoparticles in the blood stream, pene-
trating the tissue, and specific binding to the target cells of
interest. Following internalization, gene delivery vectors are
challenged by intracellular barriers, including endosome en-
trapment and nucleic acid unpacking from vectors. Among
these barriers, escaping the reticuloendothelial system (RES)
uptake and endosome will be focused in this review.
2. Strategies for Nanoparticles Escaping
RES Uptake
The applications of siRNA in vitro and in vivo are hampered
by their high molecular weight, negative charge, low stability,
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and rapid blood clearance [9–11]. Approaches to overcome
these drawbacks have relied on nonviral siRNA carriers based
on cationic polymers or lipids. Cationic vectors suffer from
fast blood clearance by the RES. Nanoparticle size and surface
charge are the two major properties strongly influencing
the clearance [12, 13]. Nanoparticle with the size of 100–
200 nm would readily accumulate and retain in the tumor
interstitium because of the enhanced permeability and
retention (EPR) effect [14–17], which is further facilitated by
the lack of a draining lymphatic system in tumor tissues. The
success of stealth nanoparticles for tumor therapy is highly
dependent on reduced RES uptake and prolonged circulation
time in the blood.
To prolong the circulation time, coating by polyethylene
glycol (PEG), or PEGylation, is the most effective method
to reduce protein adsorption in vivo and thereby helps to
avoid the RES system [18–22]. Although there are successful
attempts to develop alternative polymers to PEG, such as
poloxamer [23, 24], polyvinyl alcohol [25, 26], poly(amino
acid)s [27], and polysaccharide [28–31], PEG is still the
most widely used material. PEG-lipid (such as PEG-DSPE)
is usually inserted into liposomes to form a hydrated layer on
the liposome surface. There are two kinds of conformation
for PEG covering the surface of nanoparticles. For PEG-
DSPE-stabilized liposomes, PEG is ready to take mushroom
conformation at low degree of PEGylation and will shift
to brush conformation as the content of PEG-DSPE is in-
creased to certain levels. The brush mode is the ideal config-
uration for protecting nanoparticles from serum absorption.
However, due to the detergent-like property of PEG-lipid,
it is difficult to form stable liposomes with high content of
PEG-lipid. To tackle this problem, Li and Huang [32, 33]
developed PEGylated liposome-polycation-DNA (LPD) na-
noparticles by inserting PEG-DSPE after formation of LPD
nanoparticles. Negative and nanosized cores were formed by
condensing DNA with protamine, which then bind cationic
lipids to form DNA/protamine-encapsulated liposomes.
The DNA/protamine cores played an important role to
stabilize liposomes by electrostatic interaction. Therefore,
LPD nanoparticles were still stable, even if 10.6% (by molar)
of PEG-lipid was incorporated into the LPD nanoparticles
[32, 33]. Stealth LPD nanoparticles were characterized
by lower liver uptake through evasion of RES uptake and
efficient delivery of siRNA to tumors [34, 35]. After 4 hours
of i.v. injection, RES uptake of LPD nanoparticles was as
low as 5–15% of the injected dose, and 30% of the dose
accumulated in the tumor. It was hypothesized that the
brushed PEG shed overtime, resulting in reducing the PEG
content in the nanoparticles and further blood clearance
[33, 36–38]. Pharmacokinetics (PK) data showing a rapid
distribution phase and not much prolonged circulation time
of the injected particles is consistent with the hypothesis.
PEG shedding, which is not well understood and requires
further study, is important for endosome escape and cargo
discharge after the nanoparticle enters into the cell by endo-
cytosis. This aspect will be discussed in Section 3.
To overcome the PEG dilemma, several strategies are de-
signed. The first strategy is to modify the nanoparticles
with tumor-specific ligand to enhance intracellular uptake.
Among the ligands, iron-saturated transferrin (Tf) has been
widely investigated to target tumor cells overexpressing Tf-
receptors [39–43]. Ogris et al. [40] demonstrated that Tf-
bearing PEG-polyethyleneimine (PEI) could selectively de-
liver plasmid into tumor, leading to 100-fold higher gene ex-
pression in tumor cells than that of other tissues. Bartlett
et al. [10] prepared siRNA-containing, Tf-targeted nanopar-
ticles. Although Tf could not enhance the accumulation of
nanoparticles in the tumor in mice, it facilitated cell uptake of
nanoparticles, thereby improved gene knockdown efficiency.
Very recently, they performed the first gene inhibition exper-
iment by administration of Tf-targeted, siRNA-containing
cyclodextrin containing polycation (CDP) nanoparticles in
humans [42] and showed that siRNA successfully silenced
the target gene in both mRNA and protein levels. In addition,
several other ligands, such as RGD [44, 45], CNGRC [46],
anisamide [35, 45, 47], and folate [48, 49], have also been
applied to target specific tumor delivery in vivo.
Ligand-mediated nanoparticles are usually internalized
into tumor cells by receptor-mediated endocytosis and finally
taken up into endosomal/lysosomal vesicles. Therefore, the
second strategy is to incorporate sheddable PEG to facili-
tate drug escape from endosomal/lysosomal vesicles. Exploit-
ing the microenvironment of tumor and acidic nature of
endosome, PEG-lipids and polyplexes with pH-sensitive
degradable spacers are used to prepare PEG sheddable lipo-
somes and cationic polymer vectors. Usually, pH-sensitive
degradable bonds are orthoester [50, 51], hydrazone [52, 53],
vinyl ethers [54], or acetals [55], and this has been re-
viewed elsewhere [56]. Enzyme cleavable PEG has also been
developed [57, 58]. In addition to use sheddable PEG, we will
discuss other methods to facilitate disruption of the endos-
omal membrane in the next section.
In addition to the PEG dilemma, another problem of
PEGylation, that is, accelerated blood clearance (ABC), has
been reported [59]. Although PEGylation could significantly
prolong the circulation time of nanoparticles in the blood,
repeated i.v. injections of the PEGylated nanoparticles result-
ed in the lost of the long-circulating characteristics [59–61].
The mechanism of ABC developed by Ishida et al. is that first
injected dose of PEGylated liposomes activates the splenic
synthesis of anti-PEG IgM, resulting in the opsonization of
the second dose of PEGylated liposomes and uptake by the
liver Kupffer cells [62–64].
To overcome the ABC problem, alternative hydrophilic
polymers (such as poly(N-vinyl-2-pyrrolidone) (PVP) and
poly(hydroxyethyl-l-asparagine) (PHEA)) [65, 66] and cleav-
able PEG-lipid derivatives [67] are used. PVP-coated nano-
particles showed improved blood circulation and no ABC
phenomenon [65]. For in vivo siRNA delivery, Kiwada group
[68] demonstrated that conventional PEG-coated siRNA-
lipoplex (PSCL) also caused anti-PEG IgM production,
which is lower than that of PEG-coated naked cationic lipo-
somes (PCL). A similar PEGylated lipid nanocarrier termed
PEGylated wrapsome (PEG-WS) was further developed for
siRNA delivery [69, 70]. Anti-PEG IgM production of the
new PEG-WS formulation is less than that of PSCL and sig-
nificantly dependant on the sequence of siRNA [70]. It shows
that anti-PEG IgM production induced by potent immune
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stimulatory siRNA is much higher, and 2′-O-methyl (2′-
OMe) uridine modification can significantly reduce anti-
PEG IgM production by inhibiting cytokine induction.
3. Strategies for Promoting Nanoparticles
Escape from Endosome
Having solved the problems with RES uptake, another chal-
lenge for siRNA delivery is to have the cargo escape from
endosomes to reach cytoplasm. Here several strategies de-
signed to enhance endosomal escape are described (Table 1).
3.1. Ion-Pair Formation. The mechanism whereby cationic
lipids destabilize endosome membrane to facilitate the endo-
somal escape of nucleic acid such as plasmid DNA or siRNA
is originally proposed by Xu and Szoka [105]. Cationic
lipids form ion pairs with anionic lipids within endosome
membrane to destabilize the endosome membrane. Because
the cross-sectional area of the combined headgroup in ion
pair is less than that of the sum of individual headgroup areas
in isolation, a “cylindrical” shape of individual charged lipids
is transformed to a “cone” shape of ion pair which further
promote the formation of the inverted hexagonal (HII) phase
as proposed by Cullis et al. [128, 129].
The exposure of the positive charge in liposomes to endo-
somal membranes is a prerequisite for electrostatic inter-
action between cationic lipids and anionic lipids. PEGylation
of liposomes for systemic drug delivery therefore inhibits
the formation of ion pairs. As mentioned in Section 2, the
shedding character of LPD nanoparticles is helpful to over-
come the PEG dilemma [32–35]. After PEG comes off the
LPD nanoparticles, cationic lipids are exposed to anionic
lipids. In this novel formulation, the brushed but sheddable
PEG not only grants LPD nanoparticles evasion of the RES
for the initial period of time such that LPD nanoparticles can
penetrate into the tumor by EPR effect but also facilitates the
endosomal escape of the cargo siRNA. Due to successful RES
evasion and endosomal escape, LPD nanoparticle is a very
promising carrier for systemic delivery of siRNA.
Obata et al. [108] synthesized zwitterionic lipids with
amino acid-modified head group. The fusogenic potential
of these liposomes with endosome-mimicking anionic mem-
brane is pH-responsive, and it increases as pH decreases. The
zeta potential of these liposomes in physiological conditions
is negative and switches to positive as pH declines, which
means that these lipoplexes may have prolonged circulation
time in the blood. The properties of these liposomes
provided great promise for drug delivery in vivo but no such
report has been seen yet.
Heyes et al. [130] synthesized 1,2-dilinoleyloxy-3-dim-
ethylaminopropane (DLinDMA) lipid with two double
bonds per alkyl chain, which has strong fusogenicity and
high gene transfection efficiency. Recently, Semple et al. [131]
developed DLinDMA derivatives by optimizing the head-
group and linker moiety to formulate stable nucleic acid-
lipid particles (SNALPs). They introduced an acid degradable
ketalized linker. SNALP formulation containing DLin-KC2-
DMA lipid presented excellent in vivo silencing activity in
liver in rodents and nonhuman primates. This novel for-
mulation could evade RES uptake and circulate in the blood
for longer time due to its low pKa under neutral pH, because
the amine head groups remain unprotonated and the zeta
potential of nanoparticles was nearly neural or negative
at pH 7.4. After the nanoparticles were internalized into
intracellular endosomes, the amine groups became proto-
nated to form cationic lipids, which was necessary to escape
endosome by ion-pair mechanism. As known, it is difficult
for liposome formulations to avoid drug leakage in the blood
on one hand and achieve rapid drug release in target tissues
on the other [132–137]. In this novel SNALP formulation,
the hydrolysis of ketal bond might increase the content
of neutral lipid in liposomes, which likely triggers siRNA
release due to reorganization of the lipid domains [138, 139]
and is key for its excellent performance at in vivo siRNA
delivery. Therefore, this formulation may be advantageous to
release cargo efficiently from both endosome and liposomes.
3.2. “Proton Sponge Effect”. Successful escape of siRNA carri-
ers from endosome and release of the payload into cytoplasm
is necessary to improve the efficiency of gene silencing. Due
to the acid nature of endosomal/lysosomal vesicles, pH-buf-
fering agents are widely exploited to promote cargo release.
Under acidic condition, various macromolecules with low
pKa amine group have been shown to exhibit “proton sponge
effect”, such as PEI and its derivates [74, 94, 140, 141]. When
the complexes formed by these compounds and nucleic acid
are internalized into the cell, these compounds are capable
of buffering the endosomal vesicle, leading to endosomal
swelling and lysis, thus releasing the nucleic acids into the cy-
toplasm.
Charge-reversal copolymers could shift their charge na-
ture between positive and negative in a pH-dependent fash-
ion [76–79, 142]. Charge conversion can occur in acidic in-
tracellular organelles such as endosome or lysosome (pH =
5∼6), and then these copolymers facilitate the endosomal
escape of nucleic acids by enhancing the capacity of “proton
sponge”. Pittella et al. [79] synthesized a hybrid nanocarrier
system composed of calcium phosphate (CaP), a block co-
polymer PEG, and a charge-conversional polymer (CCP) to
deliver siRNA. Confocal laser scanning microscopic observa-
tion confirmed that CCP was helpful for endosomal escape
of siRNA with the nanoparticles. This hybrid nanocarrier
system achieved significant knockdown of vascular endothe-
lial growth factor (VEGF) in PanC-1 cells with low cyto-
toxicity. Guo et al. prepared charge-reversal functionalized
gold nanoparticles (CRFGNs) with cis-aconitic anhydride-
functionalized poly(allylamine) (PAH-Cit) [75]. The charge
reversion of PAH-Cit was confirmed by polyacrylamide gel
electrophoresis and confocal laser scanning microscopy. In
vitro quantification of lamin A/C protein expression by
western blot indicated that the knockdown efficiency of
siRNA delivered by CRFGN was dose-dependent in Hela cell
line. At 10:1 Au : siRNA ratio, siRNA delivered by CRFGN
achieved the highest (80.0%) knockdown efficiency, which
is better than Lipofectamine 2000 which inhibited about
66.0%. CRFGN achieved similar results in DNA transfection
experiments.
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In fact, layered double hydroxide (LDH) [112], calcium
phosphate [116, 124], and some other inorganic nanoparti-
cles [118] also belong to materials which are able to deplete
protons in acid environment. Because these nanoparticles
could be degraded in acidic buffer, they are also able to
release cargo from endosomal vesicles. For example, siRNA-
loaded LDH nanoparticles [112] were dissolved due to the
low pH in the endosome, which facilitated cargo escape from
endosomes into the cytoplasm and significant downregu-
lation of protein expression in HEK293T cells. Carbonate
apatite nanoparticles [117] were developed to facilitate
siRNA escape from the endosomes. It was remarkable
that carbonate apatite nanoparticles could efficiently silence
reporter genes at a low dose and were more efficient than
Lipofectamine. Calcium phosphate has been widely used in
biomaterials due to excellent biocompatibility. In vitro gene
transfection efficiency of calcium phosphate nanoparticles
with hydroxyapatite phase structure was found to be higher
than that of the commercial transfecting reagent Polyfect
[116]. Nevertheless, these particles are not stable and readily
form large aggregates; therefore their in vivo applications
are limited. To synthesize stable siRNA-loaded calcium phos-
phate, Kataoka et al. [113–115] utilized PEG-polycarboxylate
block copolymer (such as PEG-b-poly(aspartic acid) and
PEG-b-poly(methacrylic acid)) to achieve stable and size-
controlled CaP nanoparticles, which showed good stability
in serum and significant gene knockdown in vitro. Incorpo-
ration of PEG-SS-siRNA instead of PEG-polycarboxylate for
stabilization achieved high PEG density in CaP nanoparti-
cles, which could be potentially useful for the systemic deliv-
ery of siRNA. The PEG-stabilized CaP nanoparticles were
observed to escape from endosome/lysosome exhibited RNAi
efficacy for in vitro gene silencing. To improve the endosomal
escape of CaP nanoparticles, a diblock copolymer composed
of PEG and a charge-reversal polymer was incorporated [79]
and resulting hybrid nanoparticles showed significant VEGF
knockdown in PanC-1 cells because of the rapid endosomal
escape. However, there is no in vivo study of PEG-stabilized
CaP nanoparticles for siRNA delivery.
Recently, Li et al. [109] prepared siRNA-encapsulated
calcium phosphate by reverse water-in-oil microemulsion
technique and then coated calcium phosphate nanoparticles
with lipid to obtain a novel siRNA formulation of lipid-
coated calcium phosphate (LCP) nanoparticle for siRNA
systemic delivery. As mentioned before, calcium phosphate
is acid-sensitive, and its degradation in endosome/lysosome
increases osmotic pressure of endosome, leading to release
of siRNA into the cytoplasm. In addition, lipid component is
well known to be helpful for nanoparticles uptake and cargo
release from endosome. Antiluciferse (luc) siRNA-loaded
LCP nanoparticles showed significant gene silencing of lucif-
erase both in vitro and in vivo with negligible immunotox-
icity. The in vivo results suggested that LCP nanoparticles
offer significant promise for siRNA delivery in clinical trails.
3.3. Membrane-Destabilizing Macromolecules. To date, there
is no kind of synthetic vector which has comparable effi-
ciency as viral vectors. Hemagglutinin protein, which is pH-
sensitive and membrane-destabilizing, helps viral vectors to
disrupt the endosome efficiently and enter the cytoplasm
[127]. The escape mechanism of hemagglutinin and other
fusion proteins is that they shift from an ionized and hydro-
philic conformation to a hydrophobic and membrane-active
conformation as the environment changes from neutral to
acidic, resulting in destabilization of the endosomal mem-
brane and its leakage subsequently. Therefore, incorporation
of membrane-destabilizing peptides is another effective
strategy to utilize the low pH environment of endosomes/
lysosomes.
To mimic the function of viral hemagglutinin protein,
many peptides [123, 143–145] and polymers [80, 146–149]
with similar properties were synthesized to enhance gene and
siRNA delivery. Among the synthetic peptides, the GALA
peptide (WEAALAEALAEALAEHLAEALAEALEALAA)
[123] was the most studied. Harashima group has developed
a kind of multifunctional envelope type nanodevice (MEND)
combining PEGylation, targeting ligand, and GALA. It was
demonstrated that GALA facilitated endosomal release of
siRNA, resulting in efficient knockdown [124–126]. In an in
vivo gene silencing study, different MENDs with antilucif-
erase siRNA were directly injected into tumors of T1080-luc-
tumor-bearing mice, and compared to unmodified MEND,
GALA-modified MEND exhibited greater gene silencing
in tumor tissues. On the other hand, poly(propylacrylic
acid) (PPAA) was the most efficient and most studied mem-
brane-destabilizing synthetic polymers, and its membrane-
destabilizing capacity could be enhanced by copolymer-
ization with hydrophobic monomers [80–84]. PPAA was
demonstrated to enhance the transfection efficiency of
cationic lipid/pDNA complexes both in vitro and in vivo
[81, 85]. PPAA is negatively charged at physiological
condition and therefore cannot condense siRNA directly.
Stayton et al. synthesized a kind of diblock polymer
composed of poly(2-(dimethylamino)ethyl methacrylate)
(PDMAEMA) to condense siRNA and a second endosomal-
releasing block composed of DMAEMA and propylacrylic
acid (PAA) in roughly equimolar ratios, together with bu-
tyl methacylate (BMA). These carriers became sharply lyt-
ic at endosomal pH range. In HeLa cells, a copolymer with
the most hydrophobic second block (highest BMA con-
tent) exhibited the best knockdown effect [86]. When the
length of endosomolytic block and its hydrophobic content
were increased, this type of copolymer could self-assemble
into spherical micelle. The cationic micelle presented much
higher knockdown efficiency at low siRNA dose as com-
pared to nonmicelle formulations. These results also indi-
cated that hydrophobic property should contribute signif-
icantly to enhancing siRNA knockdown efficiency [87]. Sim-
ilarly, Lin et al. [150] synthesized a comb-like polymers con-
structed by a copolymer of pH-sensitive EAA monomers
and hydrophobic BMA or hexyl methacrylate (HMA) as the
backbone and a second copolymer of hydrophobic HMA
and cationic trimethylaminoethylmethacrylate (TMAEMA)
at a 50/50 molar feed ratio as grafts. The grafts were linked
to the backbone by the acid-labile hydrazone bond. These
comb-like polymers could deliver anti-GAPDH siRNA mole-
cules and successfully silenced GAPDH expression at both
the mRNA and protein levels in MCF-7 cells.
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3.4. Hydrophobic Modifications of Cationic Polymers. For
gene delivery, it has been widely reported that hydrophobic
modification of cationic polymers could improve the in-
teraction between vectors, resulting in more efficient escape
by lysis of the endosomes and therefore higher gene trans-
fection efficiency [151–155]. Recently, hydrophobic-modi-
fied or amphiphilic cationic copolymers are also used as
vectors to deliver siRNA [89–91, 94–98, 156]. Kim et al.
[88, 89] synthesized water soluble lipopolymer (WSLP)
by conjugating cholesterol with short PEI (1.8 kDa) or
oligoarginine. WSLP/siRNA complexes showed successful
VEGF knockdown in vitro and significant repression of
tumor growth in vivo via intratumoral injection. Similarly,
branched PEI (25 kDa) derivatives, such as PEI modified by
oleic acid and stearic acid [90], tyrosine [92] or PEI grafted
with hydrophobic poly(γ-benzyl L-glutamate) segment [93],
and low molecular weight PEI (800 Da) modified by Michael
addition with alkyl acrylates [91], could condense siRNA
into more stable nanoparticles and present better siRNA
silencing effect than PEI and were comparable to some of the
commercially available transfection agents. These branched
PEI derivatives also have low cytotoxicity.
Mao et al. [96, 97] reported self-assembled nanopar-
ticles of monomethoxy poly(ethylene glycol)-block-poly(ca-
prolactone)-block poly(2-aminoethyl ethylene phosphate)
(PPEEA) (mPEG-b-PCL-b-PPEEA). Micellar nanoparticles
have several advantages over hydrophilic cationic coploly-
mers. For example, micellar nanoparticles could load nucleic
acids and hydrophobic anticancer drugs simultaneously.
Anticeramidase siRNA-loaded nanoparticles showed signif-
icant gene knockdown activities toward the endogenous
acid ceramidase gene in vitro and significant inhibition
of tumor growth in a BT474 xenograft murine model via
tail vein injection. Evaluation of immunotoxicity indicated
that this delivery system did not induce immune response.
Xiong et al. [95] synthesized a type of biodegradable amphi-
philic poly(ethylene oxide)-block-polycaprolactone (PEO-b-
PCL) with grafted polyamines for siRNA delivery. These
polyamine-grafted PEO-b-PCL micelles could efficiently de-
liver MDR-1-targeted siRNA to silence P-gp expression in
vitro and showed effective endosomal escape after cellular
uptake.
Additionally, amphiphilic copolymers have been ex-
plored in an effort to deliver nucleic acids and hydrophobic
drug paclitaxel into cancer cells [98, 99]. Zhu et al. [98] syn-
thesized PDMAEMA-PCL-PDMAEMA triblock copolymers
by RAFT polymerization method. Polymeric micelles/anti-
GFP siRNA complexes showed more efficient knockdown
than PDMAEMA (20 kDa) and PEI (25 kDa) in MDA-MB-
435-GFP cells, and codelivery of VEGF siRNA and paclitaxel
with polymeric micelles/siRNA complexes achieved syner-
gistic effects in inhibiting tumor cell growth in vitro.
3.5. pH-Sensitive Degradable Vectors. In addition to the abil-
ity to escape from endosomes, the ideal siRNA delivery
vectors should be able to release siRNA into the cytoplasm.
Among the pH-sensitive bonds, acetal bond has been widely
used to construct intelligent macromolecules or lipid vectors
for drug delivery [100–103, 131, 157], due to its fast degrada-
tion in endosomal environment. Materials containing acetal
bonds are supposed to be degraded in endosomes which pre-
cedes the release of their cargo. Hydrolysis of acetal bond will
consume hydrogen, which also helps cargo escape from en-
dosome by increasing endosomal osmotic pressure.
Shim and Kwon [101, 157, 158] developed acid-degrad-
able ketalized branched PEI and linear PEI. These derived
PEIs showed significant gene transfection efficiency and
siRNA knockdown effect when compositions of the poly-
mers were optimized. Some of them could selectively re-
lease siRNA from the endosome into cytoplasm with re-
duced cytotoxicity. To achieve efficient dissociate of carrier
with nucleic acids, they synthesized PEG-conjugated acid-
degradable poly(ketalized serine) [100] and degradable pol-
yspermine by Michael addition [103].
4. Conclusions
To date, lipid and polymeric nanoparticles have already
been widely used for siRNA delivery. For nanoparticles to
efficiently deliver siRNA into target tissue and silence target
genes, they must overcome two major hurdles: RES uptake
and endosome entrapment. Long-circulation property is the
prerequisite for nanoparticles to carry most of the siRNA
cargo into the target site of interest. Circulation half-life
in the blood can be improved by PEGylation or coating
a neural and anionic shell. Facilitating endosomal escape
is another important strategy in improving drug bioavail-
ability. Incorporation of sheddable-PEG into nanoparticles
can help solve the PEG dilemma and promote nanoparticles
to escape from endosomes. Tested strategies exploiting ion
pair formation, “proton sponge effect”, or adding endosome
destabilizing agents are effective in improving endosome
escape. However, most of these endosome escape mecha-
nisms are not compatible with RES evasion such that only
local administration of the dosage form can be attempted.
Some newly developed nanoparticles (LPD and LCP), which
are able to escape from the endosome, deassemble, and
release siRNA simultaneously, certainly represent a class of
improved vectors for siRNA delivery in vivo.
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